Cerus Corporation is adjusting its previously stated product revenue guidance range. The Company expects full-year 2023 product revenue to be in the range of $155 million to $158 million. The revision is due in part to the delay in signing the now executed IFC sales agreement with one of the largest U.S. producers of cryoprecipitate.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.8 USD | +1.69% | -0.55% | -16.67% |
May. 02 | Transcript : Cerus Corporation, Q1 2024 Earnings Call, May 02, 2024 | |
May. 02 | Earnings Flash (CERS) CERUS CORPORATION Posts Q1 Revenue $43.4M, vs. Street Est of $38.4M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.67% | 333M | |
+14.21% | 130B | |
-7.72% | 11.09B | |
-1.95% | 8.56B | |
+40.43% | 5.62B | |
-27.04% | 4.41B | |
+7.47% | 3.41B | |
-15.26% | 2.6B | |
-12.01% | 2.07B | |
-13.56% | 1.92B |
- Stock Market
- Equities
- CERS Stock
- News Cerus Corporation
- Cerus Corporation Provides Product Revenue Guidance for the Full-Year 2023